The possibility of functional roles played by platelets in close alliance with cancer cells has inspired the design of new biomimetic systems that exploit platelet-cancer cell interactions. Here, the role of platelets in cancer diagnostics is leveraged to design a microfluidic platform capable of detecting cancer-derived extracellular vesicles (EVs) from ultrasmall volumes (1 µL) of human plasma samples. Further, the captured EVs are counted by direct optical coding of plasmonic nanoprobes modified with EV-specific antibodies. Owing to the inherent properties of platelets for multifaceted interaction with cancer cells, the microfluidic chip equipped with a biologically interfaced platelet membrane-cloaked surface (denoted "PLT-Chip") can capture a significantly higher number of EVs from multiple types of cancer cell lines (prostate, lung, bladder, and breast) than the normal cell-derived EVs. Furthermore, this chip allows the monitoring of the growth of tumor spheroids (100 µm-2.5 mm) and clearly distinguishes the plasma of cancer patients from that of normal healthy controls. This robust, multifaceted, and cancer-specific binding affinity, coupled with excellent biocompatibility, is a unique feature of platelet membrane-cloaked surfaces, which therefore represent promising alternatives to antibodies for application in EVs-based cancer theranostics.